"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(erythromycin topical) Solution 1.5%
For Dermatologic Use Only - Not for Ophthalmic Use
STATICIN (erythromycin topical solution 1.5%) Topical Solution contains erythromycin for topical derma-tologic use. Erythromycin is a macrolide antibiotic produced from a strain of Saccaro- polyspora erythraea (formerly Streptomyces erythreus). It is a base and readily forms salts with acids.
Chemically, erythromycin is C37H67NO13. It has the following structural formula:
Erythromycin has the molecular weight of 733.94. It is a white to grayish white or pale yellow crystalline powder.
Each mL of STATICIN (erythromycin topical solution 1.5%) contains 15 milligrams of erythromycin in a base of alcohol, propylene glycol, laureth-4 and fragrance.
Last reviewed on RxList: 2/3/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Staticin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.